Resources from the same session
LBA68 - FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Presenter: David Planchard
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA69 - Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): A randomized multicenter study
Presenter: Yi Hu
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA68 and LBA69
Presenter: Daniel Shao Weng Tan
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
LBA70 - OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)
Presenter: Yoshiro Nakahara
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA71 - A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
Presenter: Xiuning Le
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA70 and LBA71
Presenter: Yi-Long Wu
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
1312MO - Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
Presenter: Enric Carcereny
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1313MO - Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy
Presenter: Benjamin Besse
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 1312MO and 1313MO
Presenter: Lizza Hendriks
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
1314MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Luis Paz-Ares
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast